Yafell Serulle
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yafell Serulle has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Marcio Yuri Ferreira
Department of Neurosurgery, Lenox Hill Hospital/Northwell Health, New York, NY
5 shared publications - David J. Langer
Department of Neurosurgery, Lenox Hill Hospital/Northwell Health
4 shared publications - Christian Ferreira
Phelps Hospital, Northwell Health
3 shared publications - Ocílio Ribeiro Gonçalves
Federal University of Piaui
3 shared publications - Ajax Elis George
New York University School of Medicine
2 shared publications David Gordon
Department of Neurosurgery, Phelps Hospital, Northwell Health, New York, USA
2 shared publications
Latest Publications
- 24 October 2025
- Published by Springer Nature in Neurosurgical Review
- Vol. 48 (1) , 1-9
Efficacy and safety of nicardipine prolonged-release implants in patients with aneurysmal subarachnoid hemorrhage: A meta-analysis of randomized controlled trials
Cerebral vasospasm (CV) is a major complication following aneurysmal subarachnoid hemorrhage (aSAH), significantly contributing to morbidity and mortality. Nicardipine Prolonged-Release Implants (NPRI) offer targeted, localized drug delivery to prevent CV. This meta-analysis evaluated NPRI’s efficacy and safety in reducing CV, mortality, and adverse events in patients with aSAH undergoing aneurysm repair. A systematic review and meta-analysis followed PRISMA guidelines. We searched PubMed, Embase, and Cochrane (inception–November 2024). Included RCTs compared NPRI plus standard care vs. standard care alone. Outcomes: CV, mortality, and adverse events. A random-effects model calculated risk ratios (RR) with 95% confidence intervals (CI). Heterogeneity was assessed via I². Registered in PROSPERO (CRD42024629347). From 214 identified records, three RCTs comprising 84 patients (NPRI group: 45; control group: 39) met inclusion criteria. NPRI significantly reduced CV incidence (RR, 0.24 [95% CI, 0.09–0.60]; P = .002) with low heterogeneity (I² = 37%). Mortality was also significantly reduced in the NPRI group (RR, 0.18 [95% CI, 0.03–0.95]; P = .044; I² = 0%). Adverse events were less frequent in the NPRI group (RR, 0.42 [95% CI, 0.18–0.97]; P = .043; I² = 0%). This meta-analysis provides preliminary evidence supporting NPRI to reduce CV, mortality, and adverse events in aSAH. Despite the small number of included studies, low heterogeneity and significant effect sizes suggest NPRI as a promising intervention. Larger-scale RCTs with extended follow-up are required to validate these findings and define NPRI’s role in clinical practice.
- 24 October 2025
- Published by Springer Nature in Neurosurgical Review
- Vol. 48 (1) , 1-9
Efficacy and safety of nicardipine prolonged-release implants in patients with aneurysmal subarachnoid hemorrhage: A meta-analysis of randomized controlled trials
Cerebral vasospasm (CV) is a major complication following aneurysmal subarachnoid hemorrhage (aSAH), significantly contributing to morbidity and mortality. Nicardipine Prolonged-Release Implants (NPRI) offer targeted, localized drug delivery to prevent CV. This meta-analysis evaluated NPRI’s efficacy and safety in reducing CV, mortality, and adverse events in patients with aSAH undergoing aneurysm repair. A systematic review and meta-analysis followed PRISMA guidelines. We searched PubMed, Embase, and Cochrane (inception–November 2024). Included RCTs compared NPRI plus standard care vs. standard care alone. Outcomes: CV, mortality, and adverse events. A random-effects model calculated risk ratios (RR) with 95% confidence intervals (CI). Heterogeneity was assessed via I². Registered in PROSPERO (CRD42024629347). From 214 identified records, three RCTs comprising 84 patients (NPRI group: 45; control group: 39) met inclusion criteria. NPRI significantly reduced CV incidence (RR, 0.24 [95% CI, 0.09–0.60]; P = .002) with low heterogeneity (I² = 37%). Mortality was also significantly reduced in the NPRI group (RR, 0.18 [95% CI, 0.03–0.95]; P = .044; I² = 0%). Adverse events were less frequent in the NPRI group (RR, 0.42 [95% CI, 0.18–0.97]; P = .043; I² = 0%). This meta-analysis provides preliminary evidence supporting NPRI to reduce CV, mortality, and adverse events in aSAH. Despite the small number of included studies, low heterogeneity and significant effect sizes suggest NPRI as a promising intervention. Larger-scale RCTs with extended follow-up are required to validate these findings and define NPRI’s role in clinical practice.
- 16 June 2025
- Published by Springer Nature in Neuroradiology
- Vol. 67 (7) , 1859-1872
Safety and efficacy of the Woven EndoBridge (WEB) device in ruptured intracranial aneurysms: a systematic review and updated meta-analysis
Background The Woven EndoBridge (WEB; Terumo) device has gained increasing recognition for treating ruptured intracranial aneurysms (RIAs) due to its ability to disrupt flow with a single implant, avoiding long-term dual antiplatelet therapy. Despite multiple studies, a comprehensive synthesis of recent evidence remains lacking. This study addresses this gap through a systematic review and meta-analysis evaluating the WEB device’s safety and efficacy in RIA management. Methods A systematic search of EMBASE, MEDLINE, Scopus, Cochrane, and the Web of Science identified studies on WEB treatment for RIAs up to January 2025. Key outcomes included implantation success, rebleeding, occlusion, retreatment, good functional outcomes (mRS 0–2) at 90 days, morbidity, mortality, and complications. A single-arm proportion analysis was conducted under a random-effects model. Results Twenty-five studies with 1,065 patients (1,077 aneurysms) were included. The implantation success rate was 98.04%, and rebleeding occurred in 0.33% of cases. Adequate and complete occlusion at 12 months were 83.77% and 59.42%, respectively. Good functional outcomes at 90 days were 87.27%, with a retreatment rate of 7.54%. Procedure-related mortality and morbidity were 0.39% and 1.39%. The overall complication rate was 12.82%, with thromboembolic and hemorrhagic events in 4.55% and 1.05% of cases, respectively. Conclusion Our findings indicate that the WEB device is a safe and effective treatment for RIAs, offering high rates of adequate occlusion, good functional outcomes, and low complication rates. This evidence reaffirms the WEB device’s safety and efficacy, supporting its wider adoption in clinical use.
- 16 June 2025
- Published by Springer Nature in Neuroradiology
- Vol. 67 (7) , 1859-1872
Safety and efficacy of the Woven EndoBridge (WEB) device in ruptured intracranial aneurysms: a systematic review and updated meta-analysis
Background The Woven EndoBridge (WEB; Terumo) device has gained increasing recognition for treating ruptured intracranial aneurysms (RIAs) due to its ability to disrupt flow with a single implant, avoiding long-term dual antiplatelet therapy. Despite multiple studies, a comprehensive synthesis of recent evidence remains lacking. This study addresses this gap through a systematic review and meta-analysis evaluating the WEB device’s safety and efficacy in RIA management. Methods A systematic search of EMBASE, MEDLINE, Scopus, Cochrane, and the Web of Science identified studies on WEB treatment for RIAs up to January 2025. Key outcomes included implantation success, rebleeding, occlusion, retreatment, good functional outcomes (mRS 0–2) at 90 days, morbidity, mortality, and complications. A single-arm proportion analysis was conducted under a random-effects model. Results Twenty-five studies with 1,065 patients (1,077 aneurysms) were included. The implantation success rate was 98.04%, and rebleeding occurred in 0.33% of cases. Adequate and complete occlusion at 12 months were 83.77% and 59.42%, respectively. Good functional outcomes at 90 days were 87.27%, with a retreatment rate of 7.54%. Procedure-related mortality and morbidity were 0.39% and 1.39%. The overall complication rate was 12.82%, with thromboembolic and hemorrhagic events in 4.55% and 1.05% of cases, respectively. Conclusion Our findings indicate that the WEB device is a safe and effective treatment for RIAs, offering high rates of adequate occlusion, good functional outcomes, and low complication rates. This evidence reaffirms the WEB device’s safety and efficacy, supporting its wider adoption in clinical use.
- 4 June 2025
- Published by Springer Nature in Neurosurgical Review
- Vol. 48 (1) , 1-9
Drug-Coated Balloon Versus Stent Angioplasty in Patients with Intracranial Atherosclerotic Disease: A Systematic Review and Meta-Analysis
Introduction Intracranial atherosclerotic disease (ICAD) is a major cause of ischemic stroke, particularly in high-risk populations. Endovascular treatment options, including drug-coated balloon (DCB) angioplasty and stent angioplasty (SA), have been explored as alternatives for patients with severe stenosis or refractory symptoms. However, the comparative efficacy and safety of these interventions remain a topic of debate. Methods A systematic search was conducted across PubMed, Embase, Cochrane, Scopus, and Web of Science up to December 2024. Studies comparing DCB to SA were included. Outcomes analyzed were symptomatic restenosis, overall restenosis rates, and recurrent ischemic events. Results Three studies with 213 patients met the inclusion criteria. DCB was associated with significantly lower rates of overall restenosis (OR: 0.22, 95% CI: 0.10–0.50, I2 = 0%,p < 0.001) and recurrent ischemic events (OR: 0.20, 95% CI: 0.07–0.63, I2 = 0%,p = 0.006). There was no statistically significant disparity between both methods concerning symptomatic restenosis (OR: 0.34, 95% CI: 0.09–1.24, I2 = 0%, p = 0.101). Conclusion This meta-analysis suggests that DCB angioplasty may be safer and more effective than SA for ICAD, with lower rates of restenosis and ischemic complications. However, the evidence is primarily based on observational studies, highlighting the need for multicenter randomized controlled trials with standardized protocols to establish further the comparative efficacy and long-term outcomes between DCB and SA in patients with ICAD.
- 4 June 2025
- Published by Springer Nature in Neurosurgical Review
- Vol. 48 (1) , 1-9
Drug-Coated Balloon Versus Stent Angioplasty in Patients with Intracranial Atherosclerotic Disease: A Systematic Review and Meta-Analysis
Introduction Intracranial atherosclerotic disease (ICAD) is a major cause of ischemic stroke, particularly in high-risk populations. Endovascular treatment options, including drug-coated balloon (DCB) angioplasty and stent angioplasty (SA), have been explored as alternatives for patients with severe stenosis or refractory symptoms. However, the comparative efficacy and safety of these interventions remain a topic of debate. Methods A systematic search was conducted across PubMed, Embase, Cochrane, Scopus, and Web of Science up to December 2024. Studies comparing DCB to SA were included. Outcomes analyzed were symptomatic restenosis, overall restenosis rates, and recurrent ischemic events. Results Three studies with 213 patients met the inclusion criteria. DCB was associated with significantly lower rates of overall restenosis (OR: 0.22, 95% CI: 0.10–0.50, I2 = 0%,p < 0.001) and recurrent ischemic events (OR: 0.20, 95% CI: 0.07–0.63, I2 = 0%,p = 0.006). There was no statistically significant disparity between both methods concerning symptomatic restenosis (OR: 0.34, 95% CI: 0.09–1.24, I2 = 0%, p = 0.101). Conclusion This meta-analysis suggests that DCB angioplasty may be safer and more effective than SA for ICAD, with lower rates of restenosis and ischemic complications. However, the evidence is primarily based on observational studies, highlighting the need for multicenter randomized controlled trials with standardized protocols to establish further the comparative efficacy and long-term outcomes between DCB and SA in patients with ICAD.
- Open Access
- 2 January 2025
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 34 (2) , 108180
P2Y12 inhibitors plus aspirin versus aspirin alone in patients with ischemic cerebrovascular events: An updated meta-analysis of randomized controlled trials
- 2 January 2025
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 34 (2) , 108180
Open AccessP2Y12 inhibitors plus aspirin versus aspirin alone in patients with ischemic cerebrovascular events: An updated meta-analysis of randomized controlled trials
- 15 August 2024
- Published by Springer Nature in Neurosurgical Review
- Vol. 47 (1) , 1-2
Dwindling clipping
- 15 August 2024
- Published by Springer Nature in Neurosurgical Review
- Vol. 47 (1) , 1-2
Dwindling clipping
- 11 April 2023
- Published by Springer Nature in Current Neurology and Neuroscience Reports
- Vol. 23 (4) , 109-119
Middle Meningeal Artery Embolization in the Management of Chronic Subdural Hematoma: a Comprehensive Review of Current Literature
Purpose of Review Chronic subdural hematoma (cSDH) is a common intracranial hemorrhagic disorder with a high incidence rate among the elderly. While small, asymptomatic cSDH may resolve spontaneously, surgical intervention has been the treatment of choice for larger, symptomatic cases. Surgical evacuation of cSDH may be associated with high rates of recurrence, and even asymptomatic cSDH cases tend to progress. Over the last few years, middle meningeal artery (MMA) embolization has proven to be a safe non-invasive treatment of choice with favorable outcomes and a low recurrence rate. The ensuing paper discusses current treatment modalities for cSDH and reviews existing literature on the anatomy of MMA and its embolization as a treatment option for cSDH. Recent Findings Recent studies show that traumatic head injury leading to subdural hemorrhage can induce neovascularization that may initiate a cycle of recurrent subdural hematoma. Distal branches of MMA supply blood to the dural layers. Several studies have revealed that embolization of the MMA can stop the neovascularization process and blood flow. In addition, patients who underwent MMA embolization had a significantly quicker brain re-expansion and lower recurrence rate. Summary Although the management of cSDH is still very much a dilemma, recent research findings bring MMA embolization to light as a promising treatment alternative and adjunctive therapy.
- 11 April 2023
- Published by Springer Nature in Current Neurology and Neuroscience Reports
- Vol. 23 (4) , 109-119
Middle Meningeal Artery Embolization in the Management of Chronic Subdural Hematoma: a Comprehensive Review of Current Literature
Purpose of Review Chronic subdural hematoma (cSDH) is a common intracranial hemorrhagic disorder with a high incidence rate among the elderly. While small, asymptomatic cSDH may resolve spontaneously, surgical intervention has been the treatment of choice for larger, symptomatic cases. Surgical evacuation of cSDH may be associated with high rates of recurrence, and even asymptomatic cSDH cases tend to progress. Over the last few years, middle meningeal artery (MMA) embolization has proven to be a safe non-invasive treatment of choice with favorable outcomes and a low recurrence rate. The ensuing paper discusses current treatment modalities for cSDH and reviews existing literature on the anatomy of MMA and its embolization as a treatment option for cSDH. Recent Findings Recent studies show that traumatic head injury leading to subdural hemorrhage can induce neovascularization that may initiate a cycle of recurrent subdural hematoma. Distal branches of MMA supply blood to the dural layers. Several studies have revealed that embolization of the MMA can stop the neovascularization process and blood flow. In addition, patients who underwent MMA embolization had a significantly quicker brain re-expansion and lower recurrence rate. Summary Although the management of cSDH is still very much a dilemma, recent research findings bring MMA embolization to light as a promising treatment alternative and adjunctive therapy.
- Open Access
- 18 October 2021
- Published by Springer Nature in Cureus
- Vol. 13 (10)
Middle Meningeal Artery Embolization and the Treatment of a Chronic Subdural Hematoma
Chronic subdural hematoma (cSDH) is a common pathology that typically affects the elderly. It is believed to occur due to injury to the dural border cells, which creates an inflammation/proliferation reaction. Ineffective repair leads to the formation of a new external layer of cells and fragile capillaries, which damage easily and can worsen the condition. Conventionally, asymptomatic cSDH is managed by observation, and symptomatic cases are treated by surgical evacuation. Unfortunately, recurrence rates of the SDH following surgical evacuation can be high. One treatment option for SDH involves embolization of the middle meningeal artery (MMA). The MMA provides blood supply to the dura mater and feeds the membrane capillaries covering the SDH. MMA embolization blocks the blood flow to this system and can promote hematoma resolution. In this paper, we review the existing literature on MMA embolization and discuss the underlying pathophysiology of cSDH.
- 18 October 2021
- Published by Springer Nature in Cureus
- Vol. 13 (10)
Open AccessMiddle Meningeal Artery Embolization and the Treatment of a Chronic Subdural Hematoma
Chronic subdural hematoma (cSDH) is a common pathology that typically affects the elderly. It is believed to occur due to injury to the dural border cells, which creates an inflammation/proliferation reaction. Ineffective repair leads to the formation of a new external layer of cells and fragile capillaries, which damage easily and can worsen the condition. Conventionally, asymptomatic cSDH is managed by observation, and symptomatic cases are treated by surgical evacuation. Unfortunately, recurrence rates of the SDH following surgical evacuation can be high. One treatment option for SDH involves embolization of the middle meningeal artery (MMA). The MMA provides blood supply to the dura mater and feeds the membrane capillaries covering the SDH. MMA embolization blocks the blood flow to this system and can promote hematoma resolution. In this paper, we review the existing literature on MMA embolization and discuss the underlying pathophysiology of cSDH.
- Open Access
- 30 June 2021
- Published by Korean Society of Cerebrovascular Surgeons/Korean Society of Endovascular Surgery in Journal of Cerebrovascular and Endovascular Neurosurgery
- Vol. 23 (2) , 136-144
Use of quantitative magnetic resonance angiography in patients with symptomatic intracranial arterial stenosis who undergo stenting: Presentation of three cases
Intracranial atherosclerotic disease (ICAD) is an important cause of ischemic stroke. The etiology of stroke in patients with ICAD could be due to several mechanisms including hypoperfusion, artery-to-artery embolism, and plaque extension over small penetrating artery ostia. Management of symptomatic ICAD includes medical and endovascular management. Quantitative magnetic resonance angiography (MRA) is a technique that allows for non-invasive measurement of large vessel blood flow in the head and neck. Here, we describe procedural and clinical outcomes on three patients who presented with symptomatic ICAD and were treated with angioplasty and stenting. Quantitative MRA was used pre- and post- procedurally to assess the effects of stenting on the intracranial blood flow. Quantitative measures of intracranial blood flow may serve as an additional triage tool in the evaluation of patients with symptomatic ICAD.
- 30 June 2021
- Published by Korean Society of Cerebrovascular Surgeons/Korean Society of Endovascular Surgery in Journal of Cerebrovascular and Endovascular Neurosurgery
- Vol. 23 (2) , 136-144
Open AccessUse of quantitative magnetic resonance angiography in patients with symptomatic intracranial arterial stenosis who undergo stenting: Presentation of three cases
Intracranial atherosclerotic disease (ICAD) is an important cause of ischemic stroke. The etiology of stroke in patients with ICAD could be due to several mechanisms including hypoperfusion, artery-to-artery embolism, and plaque extension over small penetrating artery ostia. Management of symptomatic ICAD includes medical and endovascular management. Quantitative magnetic resonance angiography (MRA) is a technique that allows for non-invasive measurement of large vessel blood flow in the head and neck. Here, we describe procedural and clinical outcomes on three patients who presented with symptomatic ICAD and were treated with angioplasty and stenting. Quantitative MRA was used pre- and post- procedurally to assess the effects of stenting on the intracranial blood flow. Quantitative measures of intracranial blood flow may serve as an additional triage tool in the evaluation of patients with symptomatic ICAD.
- Open Access
- 8 October 2020
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 11, 330
Fusiform superior cerebellar artery aneurysm treated with flow diversion: A case report
Background: Fusiform aneurysms of the distal superior cerebellar artery are rare and challenging to treat. Due to the rarity of these lesions, there is little consensus regarding their management. Treatment options have traditionally included parent artery sacrifice with either an endovascular approach or microsurgical clipping. Given the small diameter of the superior cerebellar artery, flow diversion has not been typically considered as a viable treatment option for these aneurysms. Case Description: A 67-year-old female presented complaining of severe sudden onset headache. Noncontrast head CT demonstrated no intracranial hemorrhage. Head CT angiogram demonstrated a 4.2 mm fusiform aneurysm in the distal right superior cerebellar artery. The patient underwent treatment with the Pipeline embolization device which was deployed in the right superior cerebellar artery covering the aneurysm. Six-month posttreatment follow-up angiogram demonstrated resolution of the aneurysm with patency of the parent vessel. Conclusion: To the best of our knowledge, this is the first report of a distal superior cerebellar artery aneurysm treated with the Pipeline embolization device. The use of a Pipeline stent to create flow diversion should be considered in a case of a fusiform aneurysm of the right superior cerebellar artery. Treatment with flow diversion may allow for the treatment of the aneurysm while preserving patency of the parent vessel.
- 8 October 2020
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 11, 330
Open AccessFusiform superior cerebellar artery aneurysm treated with flow diversion: A case report
Background: Fusiform aneurysms of the distal superior cerebellar artery are rare and challenging to treat. Due to the rarity of these lesions, there is little consensus regarding their management. Treatment options have traditionally included parent artery sacrifice with either an endovascular approach or microsurgical clipping. Given the small diameter of the superior cerebellar artery, flow diversion has not been typically considered as a viable treatment option for these aneurysms. Case Description: A 67-year-old female presented complaining of severe sudden onset headache. Noncontrast head CT demonstrated no intracranial hemorrhage. Head CT angiogram demonstrated a 4.2 mm fusiform aneurysm in the distal right superior cerebellar artery. The patient underwent treatment with the Pipeline embolization device which was deployed in the right superior cerebellar artery covering the aneurysm. Six-month posttreatment follow-up angiogram demonstrated resolution of the aneurysm with patency of the parent vessel. Conclusion: To the best of our knowledge, this is the first report of a distal superior cerebellar artery aneurysm treated with the Pipeline embolization device. The use of a Pipeline stent to create flow diversion should be considered in a case of a fusiform aneurysm of the right superior cerebellar artery. Treatment with flow diversion may allow for the treatment of the aneurysm while preserving patency of the parent vessel.
- 21 December 2017
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 39 (1) , E7
Reply:
We thank Onder and Hanalioglu for their comments on our article, “Lumbar Puncture Test in Normal Pressure Hydrocephalus: Does the Volume of CSF Removed Affect the Response to Tap?” Our work, though retrospective, casts doubt on the use of a high-volume spinal tap of >30 mL in the assessment of
- 21 December 2017
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 39 (1) , E7
Reply:
We thank Onder and Hanalioglu for their comments on our article, “Lumbar Puncture Test in Normal Pressure Hydrocephalus: Does the Volume of CSF Removed Affect the Response to Tap?” Our work, though retrospective, casts doubt on the use of a high-volume spinal tap of >30 mL in the assessment of